| Bioactivity | α-Glucosidase-IN-57 (Compound 10c) is a competitive and orally active α-glucosidase inhibitor with an IC50 value of 0.180 μM and a Ki of 0.15 μM. α-Glucosidase-IN-57 can reduce fasting and overall blood glucose levels in mice, and can be used for anti-diabetes research[1]. |
| Invitro | α-Glucosidase-IN-57 (Compound 10c) (0, 0.045, 0.09, 0.18 μM) 与底物 p-NPG (HY-W039892) (1-16 μM) 竞争同一个 α-葡萄糖苷酶的活性位点，是一种强效的竞争性 α-glucosidase 抑制剂[1]。 MCE has not independently confirmed the accuracy of these methods. They are for reference only. 0 --> α-Glucosidase-IN-57 相关抗体: |
| In Vivo | α-Glucosidase-IN-57 (Compound 10c) (250, 500, 1000 mg/kg; 口服; 72 小时) 在 Wistar albino 大鼠模型中表现出良好的耐受性和安全性[1]。α-Glucosidase-IN-57 (10, 25, 50 mg/kg; 口服; 每天一次，共 28 天) 在糖尿病的 Wistar albino 大鼠模型中具有降糖活性，包括降低空腹血糖水平，改善葡萄糖耐量，并可能改善胰腺组织的胰岛结构[1]。 MCE has not independently confirmed the accuracy of these methods. They are for reference only. Animal Model: |
| Formula | C32H23FN4OS |
| Molar Mass | 530.61 |
| Transport | Room temperature in continental US; may vary elsewhere. |
| Storage | Please store the product under the recommended conditions in the Certificate of Analysis. |
| Reference | [1]. Khalili Ghomi M, et al. Evaluation of novel 2-(quinoline-2-ylthio)acetamide derivatives linked to diphenyl-imidazole as α-glucosidase inhibitors: Insights from in silico, in vitro, and in vivo studies on their anti-diabetic properties. Eur J Med Chem. 2024 Apr 5;269:116332. |